期刊文献+

“精准医学”模式下胰腺癌防治的探索与进展 被引量:3

Exploration and progress in prevention and treatment of pancreatic cancer under the“precision medicine”model
下载PDF
导出
摘要 胰腺癌是恶性程度较高的消化系统肿瘤之一,由于其隐匿性强、预后差、复发率高以及治疗过程中不断产生的耐药性,所导致的疾病负担日益加重,同时也促进了基础及临床研究的不断进步。近年来,随着精准医学理念的提出,基于二代测序开展的靶向治疗、免疫治疗等技术为胰腺癌的诊断和治疗提供了新机遇。本文就目前胰腺癌在精准医学治疗领域中的研究热点进行综述,以期能为胰腺癌的基础与临床研究提供一定的参考价值。 Pancreatic cancer is one of the most malignant tumors in the human digestive system.Due to its strong concealment,poor prognosis,high recurrence rate and drug resistance,the disease burden caused by pancreatic cancer is gradually increasing.This increasing disease burden has also led to advances both in basic medical and clinical research.In recent years,targeted therapy and immunotherapy based on nextgeneration sequencing provide new opportunities for the diagnosis and treatment of pancreatic cancer.This article summarized the current research hotspots in the field of precision medicine in the treatment of pancreatic cancer,hoping to provide some reference values for the basic medical and clinical research in pancreatic cancer.
作者 雷洋洋(综述) 王小林(审校) LEI Yang-yang;WANG Xiao-lin(Shanghai Institute of Medical Imaging,Shanghai 200032,China;Department of Interventional Radiology,Zhongshan Hospital,Fudan University,Shanghai 200032,China)
出处 《复旦学报(医学版)》 CAS CSCD 北大核心 2021年第2期255-260,共6页 Fudan University Journal of Medical Sciences
基金 上海市慈善基金会荣昶专项基金(Q2015-024)。
关键词 胰腺癌 二代测序 免疫治疗 精准医学 pancreatic cancer next-generation sequencing immunotherapy precision medicine
  • 相关文献

参考文献4

二级参考文献34

  • 1Herbert J,Coffin J.Reducing patient risk for human papillomavirus infection and cervical cancer[J].J Am Osteopath Assoc,2008,108(2):65-70.
  • 2Klisz C,Kaplan C.HPV prevention update.New vaccine offers additional options[J].Adv Nurse Pract,2009,17(11):28-29.
  • 3Gardner TA,Elzey BD,Hahn NM.Sipuleucel-T(Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer[J].Hum Vaccin Immunother,2012,8(4):534-539.
  • 4Noguchi M,Sasada T,Itoh K.Personalized peptide vaccination:a new approach for advanced cancer as therapeutic cancer vaccine[J].Cancer Immunol Immunother,2013,62(5):919-929.
  • 5Itoh K,Yamada A.Personalized peptide vaccines:a new therapeutic modality for cancer[J].Cancer Sci,2006,97(10):970-976.
  • 6Ito M,Shichijo S,Miyagi Y,et al.Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes[J].Int J Cancer,2000,88(4):633-639.
  • 7Nakao M,Shichijo S,Imaizumi T,et al.Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL[J].J Immunol,2000,164(5):2565-2574.
  • 8Yang D,Nakao M,Shichijo S,et al.Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients[J].Cancer Res,1999,59(16):4056-4063.
  • 9Minami T,Matsueda S,Takedatsu H,et al.Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles[J].Cancer Immunol Immunother,2007,56(5):689-698.
  • 10Krystal GW,DeBerry CS,Linnekin D,et al.Lck associates with and is activated by Kit in a small cell lung cancer cell line:inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1[J].Cancer Res,1998,58(20):4660-4666.

共引文献10

同被引文献7

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部